Using Social Media for PR and Patient Recruitment

Presented by Jeffree Itrich Sr. Communications and Recruitment Specialist ADCS, University of California San Diego

0

LZHEIMER'S DISEASE 🕗 COOPERATIVE STUDY

Electronic Media Evolves

- The media world is changing constantly.
- Social media and the internet changed how we communicate.
- Credible news comes from many electronic sources other than print, television and radio.
- To thrive, traditional media outlets must embrace electronic and social media.





What Exactly is Social Media?

- Social media are websites and applications used for social networking - allowing people to interact through website.
- Social networking is "the use of dedicated websites and applications to communicate with other users, or to find people with similar interests to one's own".*

* Oxford English Dictionary

Examples of Social Media

- Facebook, Twitter, LinkedIn, TumbIr (microblogging), YouTube, Google+, blogs, video/photo sharing, online encyclopedias (Wikipedia), Pinterest.
- Began as a way for people to connect and recommend others for linkage.
- Has grown to include business, academic and commercial communities.



More Ways to Engage Online:

- <u>http://www.indiegogo.com</u> a crowdfunding site that finds donations to support projects.
- <u>http://www.kickstarter.com</u> the world's largest funding program for creative projects.
- <u>http://crowdsourcing.org</u> lists wide variety of crowd sourcing websites offering a wide variety of help.

Social Media Stats

- Nielsen research: Americans spend 23% of their online time on social networks (SN) & blogs.
- Average US internet user spends 32 hrs online each month = the equivalent to 4 million years online.
- Pew Research Center: 2/3 of adults using SN up 29% from 2008. 57% of American adults web surf for health information.
- Nielsen reports twice as many Americans 50+ visit social sites compared to the under 18 users.
- Dazeinfo reports that 1.43 billion internet users will log onto SN sites in 2012.

More Stats ... Think caregivers

- 57% of Facebook and 59% of Twitter users are women.
- 28% of Facebook users are 35 and older. 28 million are people 45+.
- 28% of Twitter's users are 30+.
- 25% of African Americans use Twitter compared to 9% of whites.
- Adults 55+ are the fastest growing age segment of SN.

What's the Facebook Story?

- As of April 2012 Facebook (FB) has 901 million active monthly users, 526 million are daily visitors.
- More than 13% of the world's population is now on FB = most popular SN in the world.
- <u>DoubleClick</u> statistics show: FB reached one trillion page views in 6/2011, making it the most visited website in the world.
- On average people spend eight hours a month on FB.

Tweet....Tweet....Tweet....

- Twitter is rapidly gaining in popularity.
- Generates over 1.6 billion search queries per day.
- Ranked as one of the 10 most-visited websites worldwide by <u>Alexa's</u> <u>web traffic</u> analysis.
- Twitter now has 140 million active users sending 340 million tweets per day.

Our Audience is Online

- It remains a common misconception that older people don't use social media.
- Social networking is growing among older users
 - Users 65+ grew 150% between 2009 and 2011 from 13% to 33%.
 - 47% of internet users ages 50-64 and 33% of internet users ages 65 and older are using social media*

*Madden, M. (2010). Older Adults and Social Media. Pew Internet, 1-13.



Beta Testing in the ADNI Trials

- The ADNI clinical trials have included funding for coordinating center recruitment activity – enabling us to beta test a number of social media tactics over the last two years.
- In ADNI, we have the full engagement of the PI - Mike Weiner, MD from UCSF - in our social and traditional media work.

The ADNI GO Trial

The Alzheimer's Disease Neuroimaging Initiative Grand Opportunity (ADNI GO) study was the first ADCS study to:

- Have a Facebook page
- Experiment in the social "mediasphere" to reach audiences.
- Use of website banner ads and electronic publication of blogs and articles.
- Since 2009, the ADNI GO FB page evolved into the ADCS FB page with both general AD news & news about all ADCS studies.





Example of ADNI GO Banner Ad





Example of ADNI GO Blog





Example of ADNI 2 Landing Page for Geotargeted Ad Campaign



Alzheimer's Disease Neuroimaging Initiative

ADNI is a landmark study to find more sensitive and accurate methods to detect Alzheimer's Disease (AD) at earlier stages and mark its progression through biomarkers. This research could speed the search for new treatments. Scientists are looking for new ways to measure changes in the brain that occur with normal aging and with the progression of mild congitive impairment, often a precursor to AD.

Seeking people who:

- · Are between 55 and 90 years of age
- Have mild cognitive impairment (MCI) or mild to moderate AD
- Willing and able to undergo test procedures

Help make a difference! Be a part of the historic ADNI study							
Name *							
Email *							
Zip Code *							
	Learn More						
We will never send you spam. Promise.							





ADNI "earned" media is the focus of ADNI 2 and enjoys a significant blog and news





The New York Times Magazine

How Does the ADCS Use Social Media Today?

- The ADCS Blog Alzheimer's Insights.
- Mike Rafii, MD (UCSD) and Neelum Aggarwal, MD (Rush) alternate weeks sending in posts. Since mid-2010 the blog has received nearly 38k views.
- When we post their articles we link the page to our FB & Twitter pages.

Example of ADCS Blog Page

ALZHEIMER'S DISEASE COOPERATIVE STUDY Advancing Alzheimer's Disease Therapeutic Research

ADCS Blog



X D - Q

MSN.co

😪 Convert 🔻 🛃 Select

Alzheimer's Insights: an ADCS Blog

Recent Post

Thursday, March 15, 2012

The Effect of Statin Drugs on Memory

The FDA recently reviewed their national database of reported adverse events, published medical literature, and randomized clinical trials to evaluate the effect of statins on cognition. Based on their review, they have decided to add memoryproblems to the list of potential side-effects of this class of medications.

The adverse event reports generally described individuals over the age of 50 years who experienced notable, but poorlydefined memory loss that was reversible upon discontinuation of statin therapy. Time to onset of the event was highly variable, ranging from one day to years after taking the statin medication. None of the cases reported were associated with Alzheimer's disease. The review also did not reveal an association between the adverse event and a specific statin, the statin dose, or any interaction between statins and other medications. Finally, the data did not suggest that statin use leads to clinically significant cognitive decline.

In this blog, I would like to review some data from the scientific literature on the effect of statins on cognition. One of the larger clinical trials to include the effect of statins on memory is the 17,802-patient study of Crestor called JUPITER. This study showed that Crestor reduced the risk of a major cardiovascular or cerebrovascular event by 44%. In these people, the risk of a heart problem during the course of the study was low: 142 of



Home > ADCS > Alzheimer's Insights: an ADCS Blog

↑ ★ ⊅

2010	
2011	
2012	

Helpful Sites

ADEAR

- Alzheimer's Association
- Alz Forum
- Alzheimer's Foundation of
- America
 Anterica
 Anterica
- ClinicalTrials.gov

About Us

The Alzheimer's Disease Cooperative Study (ADCS) was formed in 1991 as a cooperative agreement between the National Institute on Aging (NIA) and the University of California, San Diego The ADCS is a major initiative for Alzheimer's disease (AD) clinical studies in the Federal government, addressing treatments for both cognitive and behavioral symptoms. This is part of the NIA Division of Neuroscience's effort to

The ADCS & Social Media Cont'd.....

- Alzheimer's Disease Information Newsletter (ADIN). This e-newsletter goes out to over 3,100 subscribers worldwide the beginning of each month.
- When it goes out we post it on adcs.org and link on FB & Twitter.
- Each week as we find AD articles of interest we post to both and to the adcs.org research news page.

Example of ADIN



Timing is Everything: Immunotherapy Results Illustrate Need for Earlier Intervention

By Michael Rafii, MD, PhD **Director**, Memory Disorders Clinic Associate Medical Core Director Alzheimer's Disease Cooperative Study University of California, San Diego

As many of you have undoubtedly read or heard, results from multiple clinical trials were reported this past summer involving both Bapinineuzimab and Solanezumab, two of the leading drug candidates under development for slowing down the progression of AD. Solanezumab and Bapineuzemab are both classified as immunotherapies. These drugs are monoclonal antibodies against beta amyloid, the protein that accumulates in the brain of patients with AD and is thought to be causative of the disease. The studies were all large, Phase 3, doubleblind, placebo-controlled trials in patients with mild-to-moderate AD.

Although the trials were negative, a possible efficacy signal was discovered in prespecified secondary analyses of Solanezumab trials, offering a glimmer of hope. When data from the two Solanezumab trials were combined, the results suggested a significant slowing of cognitive decline in the overall study population. Furthermore, a statistically significant effect on cognition was noted in the mild AD patient subgroup, but not moderate AD subgroup, as compared to placebo. In its release of the trial results, Lilly emphasized that these are the first Phase III data with an anti-beta amyloid agent that appear to show a slowing of cognitive decline, and that the pooled data support the amyloid hypothesis.

The results indicate that drugs against beta-amyloid will need to be tested even earlier in the course of the disease, perhaps in the prodromal stage where symptoms are even milder. This concept of earlier treatment is akin to the need to start cholesterol medication years before a heart attack occurs in order to derive benefit from its use.

Despite the negative results for Bapineuzemab, Pfizer and Johnson & Johnson remain committed to its development as a potential therapy, and in fact, will continue with another trial of bapi that is being delivered as a subcutaneous injection, rather than intravenous treatment. This method of drug delivery may actually overcome some of the barriers faced by intravenous Bapineuzemab, in that the drug may linger in the system for longer by virtue of the subcutaneous route, and have longer access times to beta-amyloid in the brain.

The Alzheimer's disease community now awaits the upcoming American Neurological Association (ANA) annual meeting and the Clinical Trials on Alzheimer's disease (CTAD) conference in October, as the full analysis on the pooled and subgroup data are released.

Clinical Trials in Alzheimer's Disease

CTAD is accepting late breaking abstracts beginning

September 1, 2012 **CTAD 2012**

http://ctad.fr/

Recent posts in the ADCS Blog....

Dementia Incidence, Cognitive Reserve and Mortality...

The Response to AD.. www.adcs.org

The new HHS website designed for AD caregivers

www.alzheimers.gov

This newsletter is prepared monthly by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. Content is intended to educate the public about AD research endeavors and other AD issues.

Questions or com-ments? Please email: brainlink@ucsd.edu

Tweet, tweet, tweet.....

	y			Search Q Hav	ve an account? Sign in 👻	
+ + + +	6	Jeffree Itric @ADCSComm The ADCS is an NIH-funded disease researchers conduct and Canada. San Diego, CA + http://www.	d national c ting AD clii	onsortium of Alzheimer's nical trials throughout the U.S.	Follow 468 TWEETS 860 FOLLOWING 524 FOLLOWERS	× *
	Follow Jeffree	ltrich	Tweets			
	Full name		0	Jeffree Itrich @ADCSComm If you or a loved one have #AD, please volunteer fo		
	Email		6	We need participants with #Alzheimer's. adcs.org/ Expand		
	Password Sig	n up	0	Jeffree Itrich @ADCSComm NFL players in at least 5 seasons are 3 times more neurodegen disease than the gen'l population.	12 Sep likely to die of a	
	Tweets > Following >			adcs.org/Alzheimers/New Expand		
			6	Jeffree Itrich @ADCSComm	12 Sep	
	Followers	>	0	Dr. Mike Rafii writes on what #Alzheimer's research can learn fro #cancer research. Fascinating blog post.		
	Favorites		adcs.org/Blog/ADCSBlog Expand			
	Lists Recent images	>	0	Jeffree Itrich @ADCSComm Dr. Mike Rafii writes about the FDA's approval of th #Exelon Patch & JNK3 elimination in #AD mice.	6 Sep ne higher dose	

Using Visuals to Harness SM.....

Videos:

 <u>NGF study video</u> on adcs.org and YouTube

<u>ADNI2 video</u> on ADCS.org



The Scope of ADCS Social Media Outreach to Date

- 862 Facebook likes (9-19-12)
- 468 Tweets to 524 followers (9-19-12)
- What does this mean?
- The social media conundrum: Lots of followers (quantity) just for the sake of high numbers vs fewer (quality) who have an interest in AD





How You Reached People (Reach and Frequency)

All Page Content 🔻

Reach?



Unique Users by Frequency?





How People Are Talking About Your Page

0

08/14/2012 - 09/10/2012 🔻

See Likes

People Who Like Your Page (Demographics and Location)



More 🕶

More 🔻

More 🔻

Why Should a Research Organization Use Social Media? <u>The Good News:</u>

- Huge free media exposure opportunity for studies.
- Can "geotarget" online ads to reach specific populations in specific geographic areas.

The Bad News:

- "Going Viral can't be planned but can be planned for. It can be a huge boost but can turn into a nightmare if the information is wrong.
- No way to stop "the message".

Increase in Web Activity on ADCS.org

Visits to the ADCS.org website as of Sept 21,2012:

- Homepage : 276,029 (up 56,169 since 3/2012)
- Blog: 37,986 (up 5,506 since 3/2012)
- ADNI GO/ADNI 2 combo: 23,948 (up 9,975 since 3/2012)
- NGF Study: 17,593 (up 3,128 since 3/2012)
- Total website visitors: 529,792 (up 155,303 since 3/2012)



How to Create Conversations with the Public Using Social Media

- Visit various social networks, find one or more that fits your organization.
- Connect with followers to provide info on current AD research.
- Converse with blogosphere to answer AD & study questions.
- Follow the 4 C rule: Consistently Create Compelling Content. If it's not interesting or you don't "show up" your followers will desert you and not come back.



An Example of Tracking SM Use

A Weekly Summary of UCSD Health Sciences in the Media

- Week of September 10
 - <u>Facebook</u>: likes 4,853 (+83) <u>Google+</u>: followers 643 (+7) <u>Tumblr</u>: followers 19,508 (+570) <u>Twitter</u>: followers 3,801 (+10) <u>YouTube</u>: views 9,040

NATIONAL & INTERNATIONAL MEDIA

- "<u>Amino-acid deficiency underlies rare form of autism</u>," Nature, features Joseph Gleeson, MD
 "<u>Gene therapy restores sense of smell to mice</u>," Nature, features Joseph Gleeson, MD
- "Alzheimer's drugs take a new tack," Nature, features Paul Aisen, MD

Final Thoughts

- Clearly your audience is online, are you?
- The media landscape is ever changing use it to benefit the public and your org.
- Utilize the opportunity for free media.
- Reach and create conversations with your audience to provide awareness and more knowledge of the cause.
- The simultaneous use of old and new media saturates the public domain and creates more exposure.
- Need help? Hire a student!







Feel free to contact the me jitrich@ucsd.edu

Or the ADCS Communications Team brainlink@ucsd.edu

